While there have been several preclinical studies investigating anti-tau treatments in animal models of TBI, a review of ClinicalTrials.gov reveals no currently registered studies using “anti-tau” agents for “traumatic brain injury.” There are two clinical trials listed which plan to study the anti-tau agent MK-2214 (NCT05466422, NCT07033494) in AD, but they are not yet recruiting. The gene discussed is MAPT; the disease is Alzheimer disease.